| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-07-4020 |
| P698 | PubMed publication ID | 18281542 |
| P50 | author | Chris Twelves | Q47067174 |
| P2093 | author name string | Paul M Loadman | |
| Alan Anthoney | |||
| Alvin Wong | |||
| Philip H Jones | |||
| Mark R Albertella | |||
| Neil Burnet | |||
| Roger M Phillips | |||
| Alshad S Lalani | |||
| Egils Vjaters | |||
| Chris Alcock | |||
| Roy Rampling | |||
| Chris R Dunk | |||
| Peter A Harris | |||
| P2860 | cites work | RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis | Q28236828 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | 1096-1104 | |
| P577 | publication date | 2008-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study | |
| P478 | volume | 14 |
| Q47103167 | A bioreducible N-oxide-based probe for photoacoustic imaging of hypoxia |
| Q39292683 | Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response. |
| Q38120850 | Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia |
| Q37439503 | Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target |
| Q39164107 | CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A. |
| Q52605912 | Chemotherapeutic Drug Based Metal-Organic Particles for Microvesicle-Mediated Deep Penetration and Programmable pH/NIR/Hypoxia Activated Cancer Photochemotherapy. |
| Q58610296 | Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine |
| Q33465375 | Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics |
| Q24617675 | Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases |
| Q36299099 | Development of an Integrated Subspecialist Multidisciplinary Neuro-oncology Service |
| Q97543194 | Dissecting and rebuilding the glioblastoma microenvironment with engineered materials |
| Q40795709 | Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases |
| Q34127983 | Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. |
| Q48371418 | Established Models and New Paradigms for Hypoxia-Driven Cancer-Associated Bone Disease. |
| Q43098086 | Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays |
| Q21142766 | Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment |
| Q28741565 | Hypoxia--implications for pharmaceutical developments |
| Q37707385 | Hypoxia-activated prodrugs in cancer therapy: progress to the clinic |
| Q61799902 | Hypoxia-targeted drug delivery |
| Q39002822 | Hypoxia: A Double-Edged Sword in Cancer Therapy |
| Q59793642 | Hypoxic Microenvironment and Metastatic Bone Disease |
| Q36573248 | Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone |
| Q38876568 | Implications of Oxygen Homeostasis for Tumor Biology and Treatment. |
| Q34605956 | Multimodality imaging of hypoxia in preclinical settings |
| Q42417074 | Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia |
| Q38722296 | Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase |
| Q36938779 | Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer |
| Q26865357 | Rational approaches to improving selectivity in drug design |
| Q45719654 | Redox-sensitive polymeric nanoparticles for drug delivery |
| Q35116798 | Six degrees of separation: the oxygen effect in the development of radiosensitizers. |
| Q37426436 | Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies |
| Q34086671 | Targeting hypoxic tumour cells to overcome metastasis. |
| Q26774750 | Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs |
| Q37565506 | The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug |
| Q90040719 | Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery |
Search more.